参考资料:
[1] Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC. Retrieved June 3, 2023, from https://www.merck.com/news/mercks-keytruda-pembrolizumab-plus-chemotherapy-before-surgery-and-continued-as-a-single-agent-after-surgery-reduced-the-risk-of-event-free-survival-events-by-42-versus-pre-operative/[2] Wakelee et al., (2023). Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer. NEJM, DOI: 10.1056/NEJMoa2302983
免责声明:药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。